Furthermore, despite breast cancer patients being treated with poly-chemotherapy, including MDR and MRP inhibitors, metastatic progression of the disease occurred, with a staggering 82.3% of patients being completely resistant to neoadjuvant therapy [121]. The gene discussed is ABCC1; the disease is breast cancer.